Document:

Exhibit
10.1

 

		
	Dainippon
    Sumitomo Pharma Co., Ltd.
	6-8,
    Doshomachi 2-chome, Chuo-ku, 
	Osaka
    541-0045, Japan 
	Phone
      : (81) 6 (6203) 4531 
	Telefax
    : (81) 6 (6203) 4533

 

June
8th, 2011

 

Dr.
Mark Pruzanski, M.D.

President
and Chief Executive Officer

Intercept Pharmaceuticals, Inc.

18
Desbrosses Street

New York, New York 10013

 

Re:
Intercept-DSP License Agreement-Amendment No. 1

 

Dear
Mark,

 

Reference
is hereby made to that certain License Agreement, dated as of March 29, 2011 between Intercept Pharmaceuticals, Inc. (“Intercept”)
and Dainippon Sumitomo Pharma Co., Ltd.(“DSP”) (the “Agreement”). In order to correctly reflect the intention
of DSP and Intercept with respect to Section 13.4 of the Agreement, we agree that the word “product” appearing immediately
before the reference to “FXR” in the 2nd line of Section 13.4 shall be deleted. Other than this, the Agreement
shall remain in full force and effect.

 

We
would appreciate your indicating your agreement with and acceptance of the amendment set forth in the preceding paragraph by signing
and dating where indicated below and providing the undersigned with a signed copy of this letter for our records. This amendment
will come into effect from the date you sign below.

 

	 	Kind
regards,
	 	 
	 	/s/ Yoshinori Oh-e
	 	Yoshinori Oh-e, Ph.D 
	 	Executive Officer 
	 	Director, Business Development 
	 	Dainippon Sumitomo Pharma Co., Ltd.

 

Accepted and agreed:

 

	/s/
 Mark Pruzanski	

Mark Pruzanski, M.D.

President/Chief Executive Officer 

Intercept Pharmaceuticals, Inc.

 

Date: June
8, 2011Exhibit 10.2

 

		Dainippon
    Sumitomo Pharma Co., Ltd.
	6-8,
    Doshomachi 2-chome, Chuo-ku,
	Osaka
    541-0045, Japan
	Phone   :
    (81) 6 (6203) 4531 
	Telefax : (81) 6 (6203)
    4533

 

September 16th, 2011

 

Dr. Mark Pruzanski, M.D.

President and Chief Executive Officer

Intercept Pharmaceuticals, Inc.

18 Desbrosses Street

New York, New York 10013

 

Re: License
Agreement-Amendment No. 2—“Confidential Information”

 

Dear Mark,

 

Reference is
hereby made to that certain License Agreement, dated as of March 29, 2011 between Dainippon Sumitomo Pharma Co., Ltd. (“DSP”)
and Intercept Pharmaceuticals, Inc. (“Intercept”)(the “License Agreement”), with respect to which DSP proposes
to amend the definition of “Confidential Information” in Article 1 of the License Agreement by adding the phrase “as
well as the terms and conditions of this Agreement and the status or results of any and all activities for Development, activities
to Commercialize, or research activities undertaken by either Party under this Agreement” following the phrase “studies
and procedures” in the last line of the definition of “Confidential Information”. The effective date of this
amendment will be September 15, 2011.

 

If this proposed
amendment is acceptable to Intercept, kindly so indicate by signing where indicated below and returning an executed copy of this
amendment to the undersigned.

 

	 	Kind
regards,
	 	 
	 	/s/ Yoshinori Oh-e 
	 	Yoshinori Oh-e, Ph.D 
	 	Executive Officer 
	 	 Director, Business Development 
	 	Dainippon Sumitomo Pharma Co., Ltd.

 

Acknowledged and Agreed:

 

	/s/ Mark Pruzanski	

Mark Pruzanski, M.D.

President/Chief Executive Officer

Intercept Pharmaceuticals, Inc.

 

Date: SEPT. 19, 2011Exhibit 10.3

 

CONFIDENTIAL TREATMENT REQUESTED UNDER
17 C.F.R. SECTIONS 200.80(b)(4) AND 240.24b-2. [*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

  

AMENDMENT NO. 3

to

LICENSE AGREEMENT

 

 

THIS AMENDMENT NO. 3 (“Amendment”)
to that certain License Agreement dated March 29, 2011 (as amended by the amendment No.1 as of June 8, 2011 and the amendment No.2
as of September 16, 2011, collectively, the “Agreement”) is made and entered into as of February 13, 2018, by and between
Sumitomo Dainippon Pharma Co., Ltd. (“Sumitomo”), a company organized under the law of Japan, having a place of business
at 6-8 Doshomachi 2-chome, Chuo-ku, Osaka 541-0045 Japan, and Intercept Pharmaceuticals, Inc. (“Intercept”), a company
organized under the law of the State of Delaware, having a place of business at 10 Hudson Yards, 37th floors, New York, NY 10001
U.S.A.

 

RECITALS

 

WHEREAS, Sumitomo and Intercept
have entered into the Agreement;

 

WHEREAS, Sumitomo provided Intercept
with a notification letter (“Notice Letter”) for the partial termination of certain rights and obligations under the
Agreement dated September 20, 2017;

 

WHEREAS, Sumitomo and Intercept
agreed after Intercept’s receipt of the Notice Letter to extend the effective date of the termination of the rights and obligations
in the Notice Letter until full execution of this Amendment;

 

WHEREAS, Sumitomo desires to obtain
the Marketing Approval for and commercialize the Product in China based on the FDA approval and Intercept agrees to cooperate with
Sumitomo;

 

WHEREAS, Sumitomo and Intercept
now desire to amend and supplement certain terms and conditions of the Agreement as hereinafter specified;

 

WHEREAS, Sumitomo and Intercept
desire that all other terms and conditions of the Agreement remain in full force and effect;

 

NOW, THEREFORE, for good and valuable
consideration, the receipt and adequacy of which are hereby acknowledged, Sumitomo and Intercept agree as follows:

 

Capitalized terms in this Amendment shall
have the same meaning as those in the Agreement, unless specifically defined otherwise in this Amendment. All Section references
are in regard to the Agreement. References to the term “Agreement” in the Agreement shall be deemed to include this
Amendment.

 

Except as expressly modified herein, the
Agreement shall remain in full force and effect in accordance with its terms. To the extent that there are any inconsistencies
between this Amendment and the Agreement, the terms of this Amendment shall supersede the Agreement.

 

     

     

    

 

		1.	The parties hereby agree to revise Section 1 DEFINITIONS “Territory” of the Agreement to be amended and restated
in its entirety as follows:

 

“Territory”
shall mean China (excluding Taiwan).

 

		2.	The parties hereby agree to revise Section 2.2 (Registration) of the Agreement to be amended and restated in its entirety as
follows:

 

2.2       Registration.
Upon DSP’s request, but only after Intercept’s receipt of the Upfront Fee set forth in Section 9.1, Intercept shall
use Commercially Reasonable Efforts, at DSP’s sole expense, to register an exclusive license (and/or this Agreement) for
DSP in the Territory with respect to the Intercept Technology and Intercept Patents, which registration shall be transferred or
assigned to DSP by Intercept immediately upon issuance for no additional consideration.

 

		3.	The parties hereby agree to revise Section 3.3 (JSC Meetings) of the Agreement to be amended and restated in its entirety as
follows:

 

3.3       JSC
Meetings. The JSC shall hold meetings as necessity requires and within sixty (60) days upon either Party’s request.
Meetings of the JSC shall be effective only if at least (1) representative of each Party is present or participating. The JSC may
meet either (i) in person at either Party’s facilities, or (ii) by audio or video teleconference. Meetings of the JSC may
be held with the consent of each Party. Each Party shall be responsible for all of its own expenses incurred in connection with
participating in the JSC meetings or any of the other committee meetings.

 

		4.	The parties hereby agree to revise Section 5.1 (Commercially Reasonable Efforts) of the Agreement to be amended and restated
in its entirety as follows:

 

5.1       Commercially
Reasonable Efforts. DSP shall use Commercially Reasonable Efforts, at its own expense, with respect to all regulatory activities
concerning the Development and Commercialization of the Products in the Field in the Territory. DSP shall have sole responsibility
for all pricing and reimbursement approval proceedings relating to each Product in the Field in the Territory, and Intercept shall
cooperate with DSP (including, but not limited to, filing, obtaining and holding the Import Drug License for the Product in the
Territory), based on mutual good faith discussions and DSP shall bear the out-of-pocket expense incurred by Intercept relating
to such cooperation solely, provided that, such expense shall be subject to prior written approval of DSP and shall not include
the expenses for the Development outside the Territory. Upon reasonable prior notice and during normal business hours, Intercept
shall, and shall cause its Affiliates and its Third Party sub-contractors to whom all or a part of the Development outside the
Territory has been entrusted or contracted, to allow the inspection by a Regulatory Authority which is required as a condition
of Regulatory Approval for the Product in the Field in the Territory. DSP shall use its Commercially Reasonable Efforts to provide
any information concerning such inspection to Intercept in a timely manner. Intercept shall manage, but shall permit DSP or its
designated representatives to be present at any inspection conducted by such Regulatory Authority. If any issue or concerns are
raised concerning the Development of the Compound or the Product in connection with the inspection by such Regulatory Authority,
Intercept shall immediately inform and discuss with DSP to solve the issue, including any recommendations made by the Regulatory
Authority.

 

 

CONFIDENTIAL TREATMENT REQUESTED UNDER
17 C.F.R. SECTIONS 200.80(b)(4) AND 240.24b-2. [*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

 

     

     

    

 

		5.	The parties hereby agree to revise Section 6.2 (Commercial Supply), 6.2.1 and 6.2.2 of the Agreement to be amended and restated
in its entirety as follows:

 

6.2       Commercial
Supply. Intercept shall supply DSP (or its Affiliates, sublicensees or sub-contractors) with all DSP’s requirements
of the Commercial Supplies. Intercept shall be responsible for the Manufacture of the Commercial Supplies in compliance with the
Specifications, GMP and all applicable Laws. The Parties shall discuss in good faith and cooperate with respect to the negotiation
of a manufacturing and supply agreement (the “Commercial Supply Agreement”) governing the supply of the Commercial
Supply by or on behalf of Intercept, to DSP (or its Affiliates, sublicensees or sub-contractors) for the Commercialization of the
Product in the Field in the Territory prior to the initiation of the Phase III Clinical Trials in the Territory. The Commercial
Supply Agreement shall contain, in addition to other customary terms, the following terms and conditions:

 

6.2.1       The
transfer price for the [*****] of the Commercial Supply supplied to DSP by or on behalf
of Intercept following receipt of Marketing Approval in the Territory shall be calculated at [*****]
percent ([*****]%) of [*****] in effect
on the date upon which each such order is sent to Intercept by DSP.

 

6.2.2       The
[*****] of the Commercial Supply supplied to DSP by or on behalf of Intercept following
receipt of Marketing Approval in the Territory shall be based on [*****] percent ([*****]%)
of [*****]. The [*****] is less than or
equal to $[*****] (the “[*****]”).
In the event that the [*****] exceeds [*****],
Intercept shall use Commercially Reasonable Efforts to reduce the [*****]. Should that
not be possible, the Parties shall discuss in good faith an increased [*****] for the
Product.

  

		6.	The parties hereby agree to revise Section 9.2.1 and 9.2.3 (Royalty Tiers) of the Agreement to be amended and restated in its
entirety as follows:

 

9.2.1       Within
thirty (30) calendar days following the occurrence of each of the events set forth below for the Product, DSP shall pay to Intercept
each of the non-refundable, non-creditable milestone payments set forth below:

 

	Milestone Event	Milestone Payment
	Development Milestones	 
	 	 
	[*****]	 
	[*****]	US$[*****]

  

 

CONFIDENTIAL TREATMENT REQUESTED UNDER
17 C.F.R. SECTIONS 200.80(b)(4) AND 240.24b-2. [*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

 

     

     

    

  

	[*****]	US$[*****]
	[*****]	US$[*****]
	[*****]	US$[*****]
	[*****]	US$[*****]
	[*****]	US$[*****]
	 	 
	[*****]	 
	[*****]	US$[*****]*

 

In
the event that the [*****] occurs [*****],
then US$[*****] milestone payment, instead of US$[*****] milestone
payment of as set forth in the chart above, shall be due.

 

For
the avoidance of doubt, [*****] shall be deemed to have occurred when [*****].

 

9.2.3       Royalty
Tiers. DSP shall pay to Intercept a royalty of [*****] percent ([*****]%)
based on total annual Net Sales of all Products in the Field in the Territory for each fiscal year (i.e. ending on March 31 of
each calendar year) in which the Net Sales of all Products in the Territory for such year is less than US$[*****]
(the “First Tier Royalty Rate”). DSP shall pay to Intercept a royalty of [*****]
percent ([*****]%) based on total annual Net Sales of
all Products in the Field in the Territory for each fiscal year in which the Net Sales of all Products in the Territory for such
year is US$[*****] or more but less than US$[*****] (the
“Second Tier Royalty Rate”). DSP shall pay to Intercept a royalty of [*****] percent
([*****]%) based on total annual Net Sales of all Products in the Field in the Territory
for each fiscal year in which the Net Sales of all Products in the Territory for such year exceeds US$[*****] (the
“Third Tier Royalty Rate”). Notwithstanding the foregoing, the transfer price for the [*****] of
the Commercial Supplies to DSP by Intercept following receipt of Marketing Approval in the Territory shall be calculated in accordance
with Section 6.2.1 and shall be deemed to [*****], and accordingly [*****];
however in no event will the transfer price be less than [*****] percent ([*****]%)
plus the applicable First, Second or Third Tier Royalty Rate.

 

The parties hereby acknowledge
and agree that (i) milestone payment of US$[*****] for [*****]
(US$[*****] and [*****] US$[*****])
and (ii) milestone payment of US$[*****] for [*****]
have already been fully paid by Sumitomo and fully received by Intercept.

 

		7.	The parties hereby agree to delete Section 9.3.2 (Reduced Royalty Rates in Japan) of the Agreement in its entirety.

 

		8.	The parties hereby agree to revise Section 9.4 (Necessary Third Party Technology Payments) of the Agreement to be amended and
restated in its entirety as follows:

 

9.4       Necessary
Third Party Technology Payments. DSP shall be entitled to deduct [*****] percent
([*****]%) of all royalties it is required to pay to a Third Party for Necessary Third
Party IP under any agreement to license or acquire intellectual property used in the Development or Commercialization of the Product
in the Field in the Territory up to a maximum of [*****] percent ([*****]%)
for purposes of Section 9.2.3, or [*****] percent ([*****]%)
for purposes of Section 9.3.1 of the applicable royalty rate.

 

 

CONFIDENTIAL
TREATMENT REQUESTED UNDER 17 C.F.R. SECTIONS 200.80(b)(4) AND 240.24b-2. [*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT
OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH
THE COMMISSION.

 

     

     

    

 

		9.	The parties hereby agree that Sumitomo hereby waives
any and all rights and option described in Section 8 COUNTRY OPTION of the Agreement.

 

		10.	The parties hereby agree that (i) any and all rights
and obligations relating to DSP Improvements specified in Exhibit A attached in this Amendment shall be assigned or transferred
from Sumitomo to Intercept, (ii) Intercept shall bear the expenses for assignment or transferring of such DSP Improvements and
(iii) Sumitomo shall have no obligation relating to such DSP Improvements that has not accrued prior to the effective date of
this Amendment. For clarification, such DSP Improvements shall be deemed to Intercept Improvements.

 

		11.	The parties hereby agree that, effective on and after the effective date of this Amendment, Section 12.5.2 (ii) (Prosecution
and Maintenance outside the Territory) of the Agreement shall apply to the prosecution and maintenance of Joint Improvement for
Japan and Korea which is specified in Exhibit B attached in this Amendment and Section 15.4.2 (i) (Prosecution and Maintenance
in the Territory) thereof shall not apply to its prosecution and maintenance.

 

		12.	The parties hereby agree that (i) any and all rights and obligations relating to the trademarks specified in Exhibit C attached
in this Amendment shall be assigned or transferred from Sumitomo to Intercept, (ii) Intercept shall bear the expenses for assignment
or transferring of such trademarks and (iii) Sumitomo shall have no obligation relating to such trademarks that has not accrued
prior to the effective date of this Amendment.

 

		13.	The parties hereby agree to replace Section 11.2 in its entirety as follows:

 

11.2       Publication.
If either party plans to publish or present the results of any studies or other data regarding the Compound or the Product
in the Field and conducted in and outside the Territory, the Party shall submit the draft of the publication, translated into
English, to the other no later than two (2) weeks prior to the planned submission for publication for review, unless such disclosure
requires immediate publication due to disclosure requirements of the U.S. Securities and Exchange Commission, the NASDAQ stock
exchange or any other stock exchange on which securities issued by a Party are traded and Intercept has advised DSP of the deadline
for disclosure in a sufficiently timely manner. As soon as a Party is aware of a deadline for submitting an abstract for an upcoming
scientific meeting, it shall notify the other Party in writing and the Parties shall use Commercially Reasonable Efforts to exchange
comments on the proposed abstract in a timely manner to facilitate the publication / presentation of the proposed abstract. Otherwise,
any publication shall need the other Party’s prior written consent, which shall not be unreasonably withheld. Any comment,
reasonable request for modification or reasonable rejection must be made within as quickly as practically possible from the receipt
of the draft. Failure to quickly make such comments shall be conclusively deemed to constitute approval of such publication or
presentation. For the avoidance of doubt, this Section 11.2 shall apply to publications made by either Party both in the Territory
and outside the Territory.

 

 

CONFIDENTIAL
TREATMENT REQUESTED UNDER 17 C.F.R. SECTIONS 200.80(b)(4) AND 240.24b-2. [*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT
OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH
THE COMMISSION.

 

     

     

    

 

		14.	The parties hereby agree to replace Section 15.1 in its entirety as follows:

 

15.1       Term;
Expiration. The term of this Agreement (the “Term”) shall commence on the Effective Date and expire
on a country-by-country basis on the later to occur of (i) the tenth (10th) anniversary of the First Commercial Sale
of the Product for the first or second indication in such country (whichever is later) or (ii) the expiration date of the Exclusive
Period in such country. Notwithstanding the foregoing, in the event that [*****] in
China has not [*****] (as defined in Section 9.2.1) by December 31, 2020, DSP may choose,
after a good faith discussion with Intercept, either that DSP pays to Intercept US$[*****]
as a milestone payment or that the Agreement is terminated as a whole, but not both.

 

		15.	The parties hereby agree that, notwithstanding the provision
of Section 15.4.5 (Surviving Provisions) of the Agreement, the obligation of Sumitomo described in Section 15.4.2 (a), (b) and
(c) for Japan and Korea shall survive four (4) years after the date of this Amendment.

  

 

CONFIDENTIAL
TREATMENT REQUESTED UNDER 17 C.F.R. SECTIONS 200.80(b)(4) AND 240.24b-2. [*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT
OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH
THE COMMISSION.

 

     

     

    

 

IN WITNESS WHEREOF, this Amendment has
been executed by the parties hereto to be made effective as of February 13, 2018, through their duly authorized officers on the
date(s) set forth below.

 

 

 

ACCEPTED AND AGREED TO:

 

	
         

        Sumitomo Dainippon Pharma Co.,
        Ltd.
	
         

        Intercept Pharmaceuticals, Inc.

	
         

         

         

        By: /s/Masayo Tada_______________

        (signature)
	
         

         

         

        By: /s/ Mark Pruzanski__________

        (signature)

	
         

        Print Name: Masayo Tada__________
	
         

        Print Name: Mark Pruzanski_____

	
         

        Title: C.E.O._____________________
	
         

        Title: C.E.O.__________________

	
         

        Date: 2/13/2018                                           
	
         

        Date: 2/9/2018                                      

  

 

CONFIDENTIAL
TREATMENT REQUESTED UNDER 17 C.F.R. SECTIONS 200.80(b)(4) AND 240.24b-2. [*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT
OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH
THE COMMISSION.

 

     

     

    

 

Exhibit A

 

The DSP Improvements
assigned to Intercept

 

	Country	Title	Serial No.	Filing Date	Status
	PCT and Taiwan	Film–Coated Tablet Having High Chemical Stability of Active Ingredient	PCT/JP2017/013214 and TW106110706	March 30, 2017	Pending
	PCT and Taiwan	Oral Preparation Having Exceptional Elutability	PCT/JP2017/013221 and TW106110707	March 30, 2017	Pending
	PCT and Taiwan	MEDICINE OBTAINED BY COMBINING FXR AGONIST AND ARB	PCT/JP2017/012448 and TW106110180	March 27, 2017	Pending

  

 

CONFIDENTIAL
TREATMENT REQUESTED UNDER 17 C.F.R. SECTIONS 200.80(b)(4) AND 240.24b-2. [*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT
OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH
THE COMMISSION.

 

     

     

    

 

Exhibit B

 

The Joint
Improvements

 

	Country	Title	Serial No.	Filing Date	Status
	See below caption*1	Compositions of Obeticholic Acid and Methods of Use	PCT/US2016/029369; US15/139,138 and their worldwide counterparts *1	April 26, 2016	Pending

 

*1) Total 44 of the countries
or areas where the patent applications have been filed are as follows:

United Arab Emirates; Argentina
(12-month, non-PCT country); Australia; Bosnia & Herzegovina; Brazil; Belize; Canada; Chile; China (current Sumitomo Territory);
Colombia; Costa Rica; Algeria; Eurasia; Ecuador; Egypt; Europe; Guatemala; Honduras; Indonesia (former Option Country); Israel;
India; Japan (former Sumitomo Territory); South Korea (former Sumitomo Territory); Morocco; Montenegro; Mexico; Malaysia (former
Option Country); Nicaragua; New Zealand; Oman; Panama; Peru; Philippines (former Option Country); Qatar; Saudi Arabia; Singapore(former
Option Country); El Salvador; Taiwan (12-month, non-PCT country) (former Option Country); Thailand (former Option Country); Tunisia;
Ukraine; United States; Vietnam (former Option Country); South Africa.

  

 

CONFIDENTIAL
TREATMENT REQUESTED UNDER 17 C.F.R. SECTIONS 200.80(b)(4) AND 240.24b-2. [*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT
OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH
THE COMMISSION.

 

     

     

    

 

Exhibit C

 

	Country	Trademark	
        Registration

        date
	
        Registration

        number
	International class	 
	Japan	OCALIVA	January 29, 2016	5823112	5	 
		January 29, 2016	5823113	5	Katakana for ”OCALIVA”
		January 29, 2016	5823114	5	Katakana for ”OCALIVA”
	QIJUVA	January 29, 2016	5823115	5	 
		January 29, 2016	5823116	5	Katakana for ”QIJUVA”
		January 29, 2016	5823117	5	Katakana for ”QIJUVA”
		January 29, 2016	5823118	5	Katakana for ”QIJUVA”
		January 29, 2016	5823119	5	Katakana for ”QIJUVA”
		January 29, 2016	5823129	5	 
	Korea	OCALIVA	August 23, 2016	40-1198094	5	 
	QIJUVA	August 23, 2016	40-1198095 	5	 
		August 23, 2016	40-1198096 	5	 

  

 

CONFIDENTIAL
TREATMENT REQUESTED UNDER 17 C.F.R. SECTIONS 200.80(b)(4) AND 240.24b-2. [*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT
OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH
THE COMMISSION.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00283-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00283-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00283-of-00352.parquet"}]]